Alaunos Therapeutics, Inc. - Common stock (TCRT)

CUSIP: 98973P309

Q3 2025 13F Holders as of 30 Sep 2025

Type / Class
Equity / Common stock
Shares outstanding
2,198,384
Total 13F shares
65,224
Share change
-5,828
Total reported value
$158,311
Price per share
$2.41
Number of holders
24
Value change
-$15,260
Number of buys
6
Number of sells
12

Quarterly Holders Quick Answers

What is CUSIP 98973P309?
CUSIP 98973P309 identifies TCRT - Alaunos Therapeutics, Inc. - Common stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Top shareholders of TCRT - Alaunos Therapeutics, Inc. - Common stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
Robert W. Postma
13D/G
Postma Robert W
9%
199,796
$615,372 $0 24 Jun 2025
Kevin S. Boyle Sr.
3/4/5
Chief Executive Officer, Director
class O/S missing
798,236
$111,993 01 Sep 2023
BlackRock, Inc.
13F
Company
0.97%
21,353
$103,562 30 Jun 2025
13F
VANGUARD GROUP INC
13F
Company
0.95%
20,972
$101,714 30 Jun 2025
13F
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
0.73%
15,946
$77,355 30 Jun 2025
13F
Raffaele Baffa
3/4/5
Chief Medical Officer
class O/S missing
280,645
$39,374 17 May 2021
UBS Group AG
13F
Company
0.31%
6,815
$33,053 30 Jun 2025
13F
Ferdinand Groenewald
3/4/5
Vice President of Finance
mixed-class rows
14,775
mixed-class rows
$30,924 18 Aug 2025
Heidi Hagen
3/4/5
Director
class O/S missing
145,889
$20,468 02 Sep 2021
MORGAN STANLEY
13F
Company
0.08%
1,798
$8,721 30 Jun 2025
13F
Christopher Bowden
3/4/5
Director
mixed-class rows
144,167
mixed-class rows
$6,197 22 Jun 2022
Steward Partners Investment Advisory, LLC
13F
Company
0.05%
1,098
$5,325 30 Jun 2025
13F
Tower Research Capital LLC (TRC)
13F
Company
0.04%
973
$4,719 30 Jun 2025
13F
OSAIC HOLDINGS, INC.
13F
Company
0.03%
695
$3,364 30 Jun 2025
13F
CIBC Private Wealth Group LLC
13F
Company
0.01%
300
$1,455 30 Jun 2025
13F
GROUP ONE TRADING LLC
13F
Company
0.01%
300
$1,455 30 Jun 2025
13F
WELLS FARGO & COMPANY/MN
13F
Company
0.01%
183
$888 30 Jun 2025
13F
BARCLAYS PLC
13F
Company
0%
100
$485 30 Jun 2025
13F
RAYMOND JAMES FINANCIAL INC
13F
Company
0%
99
$480 30 Jun 2025
13F
Federation Des Caisses Desjardins du Quebec
13F
Individual
0%
86
$417 30 Jun 2025
13F
BANK OF AMERICA CORP /DE/
13F
Company
0%
85
$412 30 Jun 2025
13F
Na Bokf
13F
Individual
0%
66
$320 30 Jun 2025
13F
Asset Dedication, LLC
13F
Company
0%
46
$224 30 Jun 2025
13F
Key FInancial Inc
13F
Company
0%
24
$116 30 Jun 2025
13F
Newbridge Financial Services Group, Inc.
13F
Company
0%
24
$116 30 Jun 2025
13F
SIGNATUREFD, LLC
13F
Company
0%
23
$112 30 Jun 2025
13F
THURSTON, SPRINGER, MILLER, HERD & TITAK, INC.
13F
Company
0%
21
$101 30 Jun 2025
13F
AdvisorNet Financial, Inc
13F
Company
0%
19
$92 30 Jun 2025
13F
BNP PARIBAS FINANCIAL MARKETS
13F
Company
0%
6
$29 30 Jun 2025
13F
INVESTMENT MANAGEMENT CORP /VA/ /ADV
13F
Company
0%
6
$29 30 Jun 2025
13F
Sunbelt Securities, Inc.
13F
Company
0%
10
$19 30 Jun 2025
13F
JPMORGAN CHASE & CO
13F
Company
0%
3
$15 30 Jun 2025
13F
Truvestments Capital LLC
13F
Company
0%
1
$5 30 Jun 2025
13F
Eleanor de Groot
3/4/5
EVP, Operations
class O/S missing
350,000
30 Mar 2022
Abhishek K. Srivastava
3/4/5
Vice President, Technical Operations
class O/S missing
125,000
15 Mar 2023
Drew Deniger
3/4/5
Vice President, Research and Development
class O/S missing
125,000
15 Mar 2023
Michael Wong
3/4/5
Vice President, Finance
class O/S missing
125,000
15 Mar 2023
James Huang
3/4/5
Director
class O/S missing
100,000
06 Jun 2023
Mary Thistle
3/4/5
Director
class O/S missing
100,000
06 Jun 2023
Holger Weis
3/4/5
Chief Executive Officer, Director
class O/S missing
13,676
18 Aug 2025
Robert Hofmeister
3/4/5
Director
class O/S missing
12,800
06 Jun 2024
Dale Curtis Hogue Jr.
3/4/5
Chief Executive Officer, Interim, Director
class O/S missing
3,000
29 Mar 2025
Melinda Lackey
3/4/5
Legal & Administration
class O/S missing
1,000
29 Mar 2025

Institutional Holders of Alaunos Therapeutics, Inc. - Common stock (TCRT) as of Q3 2025

As of 30 Sep 2025, Alaunos Therapeutics, Inc. - Common stock (TCRT) was held by 24 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 65,224 shares. The largest 10 holders included BlackRock, Inc., VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, MORGAN STANLEY, Tower Research Capital LLC (TRC), UBS Group AG, OSAIC HOLDINGS, INC., CIBC Private Wealth Group LLC, WELLS FARGO & COMPANY/MN, and Blue Trust, Inc.. This page lists 24 institutional shareholders reporting positions in this security for the Q3 2025 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q3 2025 vs Q2 2025 Across Filers

Q2 2025 holders
25
Q3 2025 holders
24
Holder diff
-1
Investor Q2 2025 Shares Q3 2025 Shares Share Diff Share Chg % Q2 2025 Value $ Q3 2025 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .